Antigen-binding fragment of durvalumab (pale green) in complex with PD-L1 (pink). PDB: 5X8M.
Monoclonal antibody
Type
Whole antibody
Source
Human
Target
CD274
Clinical data
Trade names
Imfinzi
Other names
MEDI4736, MEDI-4736
AHFS/Drugs.com
Monograph
MedlinePlus
a617030
License data
US DailyMed: Durvalumab
Pregnancy category
AU: D[1]
Routes of administration
Intravenous
ATC code
L01FF03 (WHO)
Legal status
Legal status
AU: S4 (Prescription only)[2][3]
CA: ℞-only /Schedule D[4][5]
UK: POM (Prescription only)
US: ℞-only[6]
EU: Rx-only[7]
Identifiers
CAS Number
1428935-60-7
PubChem CID
249565666
IUPHAR/BPS
7985
DrugBank
DB11714
ChemSpider
none
UNII
28X28X9OKV
KEGG
D10808
Chemical and physical data
Formula
C6502H10018N1742O2024S42
Molar mass
146322.36 g·mol−1
Durvalumab,[8] sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca.[9] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).[medical citation needed]
Durvalumab is an immune checkpoint inhibitor drug.[10]
^"Durvalumab (Imfinzi) Use During Pregnancy". Drugs.com. 30 August 2019. Archived from the original on 29 August 2021. Retrieved 7 February 2020.
^"Imfinzi (AstraZeneca Pty Ltd)". Therapeutic Goods Administration (TGA). 5 December 2022. Archived from the original on 18 March 2023. Retrieved 9 April 2023.
^"Regulatory Decision Summary - Imfinzi". Health Canada. 23 October 2014. Archived from the original on 7 June 2022. Retrieved 6 September 2022.
^"Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
^Cite error: The named reference Imfinzi FDA label was invoked but never defined (see the help page).
^"Imfinzi EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 28 August 2021. Retrieved 30 September 2020.
^World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4). Archived (PDF) from the original on 28 August 2021. Retrieved 6 September 2022.
^"Durvalumab (Imfinzi)". U.S. Food and Drug Administration (FDA). Archived from the original on 8 May 2017. Retrieved 6 May 2017.
^Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
Durvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin...
Evaluation and Research. "Approved Drugs – Durvalumab (Imfinzi)". fda.gov. Retrieved 6 May 2017. "FDA approves durvalumab after chemoradiation for unresectable...
FDA : Drugs (May 31, 2022) "FDA approves tremelimumab in combination with durvalumab for unresectable hepatocellular carcinoma". Food and Drug Administration...
combination with durvalumab, for the treatment of adults with unresectable hepatocellular carcinoma. Tremelimumab in combination with durvalumab and platinum-based...
dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Durvalumab, (Imfinzi) is an immune checkpoint inhibitor that blocks the PD-L1 protein...
combination chemotherapy and radiotherapy along with the immunotherapy durvalumab. Combined chemotherapy and radiation enhances survival compared to chemotherapy...
exhibits better efficacy than other PD-1 inhibitors, such as avelumab and durvalumab, in dMMR advanced endometrial cancers. Efficacy of the drug is measured...
COPD, asthma, and many types of cancer. Major phase III trials included: durvalumab (anti-PD-L1) tremelimumab (anti-CTLA-4) moxetumomab pasudotox (anti-CD22)...
Global Information